Competing interests
Y.R.M.-G. reports travel, accommodation and expenses from AstraZeneca and Loxo Oncology/Eli Lilly; acknowledges honoraria from Virology Education and Projects in Knowledge (for a CME program funded by an educational grant from Amgen); has been on an advisory board for Revolution Medicines; and has consulted for AbbVie. She acknowledges associated research funding to the institution from Mirati Therapeutics, Bristol Myers Squibb/ER Squibb & Sons, Loxo Oncology at Eli Lilly, Elucida Oncology, Taiho Oncology, Hengrui USA, Ltd/Jiangsu Hengrui Pharmaceuticals, Luzsana Biotechnology, Endeavor Biomedicines, AbbVie, Erasca and Arvinas. She is an employee of Memorial Sloan Kettering Cancer Center, which has an institutional interest in Elucida; she acknowledges royalties from Rutgers University Press and Wolters Kluwer; and acknowledges food/beverages from Endeavor Biomedicines, AstraZeneca and Eli Lilly, and other services from Amgen, Loxo Oncology/Eli Lilly, AbbVie, Arvinas and Taiho Oncology. She acknowledges receipt of training through an institutional K30 grant from the NIH (CTSA UL1TR00457), and has received funding from a Kristina M. Day Young Investigator Award from Conquer Cancer, the ASCO Foundation, endowed by Dr Charles M. Baum and Carol A. Baum. She has also received funding from the Fiona and Stanley Druckenmiller Center for Lung Cancer Research, the Andrew Sabin Family Foundation, the Society for MSK, the Squeri Grant for Drug Development, and a Paul Calabresi Career Development Award for Clinical Oncology (NIH/NCI K12 CA184746) as well as through NIH/NCI R01 CA279264. Z.K.S. has intellectual property rights in SOPHiA Genetics and serves as an associate editor for JCO Precision Oncology and as a section editor for UpToDate. Z.K.S.’s immediate family member serves on the board of directors for Adverum Biotechnologies, is co-founder, chief medical officer and president for Blue Gen Therapeutics Foundation, and serves as a consultant in Ophthalmology for Beacon Therapeutics and Regeneron Pharmaceuticals outside the submitted work.
